Skip to main content

Table 3 Multivariate analysis of factors associated with underutilization of inhaled corticosteroids in TASH chest clinic from 1 May to 31 September 2014 (n = 131)

From: Assessment of inhaled corticosteroids use and associated factors among asthmatic patients attending Tikur Anbessa Specialized Hospital, Ethiopia

Variables Underutilization of ICS COR (95% CI) AOR
Yes n (%) No n (%)
Monthly income in ETB (=120)a
 ≤1200 56 (78.3) 17 (21.7) 8.10 (2.19–30.00) a 5.35 (1.10–22.16)
 1201–2500 15 (51.9) 13 (48.1) 2.42 (0.59–9.82) 1.46 (0.29–7.22)
 >2500 10 (30.8) 9 (69.2) 1.01 1.00
Duration of asthma in years
 ≤21 36 (56.9) 28 (43.1) 1.00 1.00
 >21 47 (72.1) 20 (27.9) 1.96 (0.91–4.21) 1.49 (0.54–4.15)
Comorbidity
 Yes 54 (71.8) 23 (28.2) 2.15 (1.001–4.65) a 3.10 (1.11–8.69) a
 No 29 (54.2) 25 (45.2) 1.00 1.00
Types of ICS products prescribed
 ICS alone 68 (73.9) 26 (26.1) 4.44 (1.88–10.62) a 4.39 (1.49–12.92) a
 ICS with LABA 15 (38.7) 21 (61.3) 1.00 1.00
Severity of asthma
 Mild 28 (61.9) 18 (38.1) 1.00 1.00
 Moderate 23 (52.5) 21 (47.5) 0.68 (0.28–1.64) 0.545 (0.16–1.87)
 Severe 32 (81.1) 9 (18.9) 2.63 (0.94–7.40) 3.17 (0.86–11.75)
  1. Variables with significant association are indicated in italics
  2. TASH Tikur Anbessa Specialized Hospital, CI confidence interval, COR crude odds ratio, AOR adjusted odds ratio
  3. a Remaining subjects were non respondents, Ethiopian per capita income is $590, price of beclate (beclomethasone) 200 μg in Ethiopia is 110 ETB